반응식
[CH3:1][C:2]1[N:3]=[CH:4][C:5]([NH:8][C:9]2[C:18]3[C:13](=[CH:14][CH:15]=[C:16]([OH:19])[CH:17]=3)[N:12]=[CH:11][N:10]=2)=[N:6][CH:7]=1.C(O[CH:23](OCC)[CH2:24][O:25][C:26]1[CH:27]=[CH:28][C:29](F)=[N:30][CH:31]=1)C.[NH:36]1[CH2:40][CH2:39][CH2:38][CH2:37]1>>[CH3:1][C:2]1[N:3]=[CH:4][C:5]([NH:8][C:9]2[C:18]3[C:13](=[CH:14][CH:15]=[C:16]([O:19][C:29]4[CH:28]=[CH:27][C:26]([O:25][CH2:24][CH2:23][N:36]5[CH2:40][CH2:39][CH2:38][CH2:37]5)=[CH:31][N:30]=4)[CH:17]=3)[N:12]=[CH:11][N:10]=2)=[N:6][CH:7]=1참가 물질
4
실험 절차
The compound of Example 38 was obtained as follows: Using 4-[(5-methylpyrazin-2-yl)amino]quinazolin-6-ol, 5-(2,2-diethoxyethoxy)-2-fluoropyridine and pyrrolidine, and in the same manner as in Example 31 or according to a method similar to it or according to a combination thereof with an ordinary method, the entitled compound (11 mg) was obtained as a pale yellow solid.
출처 및 근거
- ORD 기록
- ord-0fe534c237614144b48b83c2aaa344c1
- 출처 데이터셋
- uspto-grants-2012_07
- 특허 번호
- US08232284B2
연결된 노트
불러오는 중…